Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2014 (2014), Article ID 461917, 10 pages
Review Article

Hyperglycemia, a Neglected Factor during Cancer Progression

1Department of Hepatobiliary Surgery, First Affiliated Hospital, Medical College, Xi’an Jiaotong University, 277 West Yanta Road, Xi’an, Shaanxi 710061, China
2Department of Anesthesiology, First Affiliated Hospital, Xi’an Jiaotong University, 277 West Yanta Road, Xi’an, Shaanxi 710061, China
3Department of Pharmaceutical Sciences, North Dakota State University, Fargo, ND 58105, USA

Received 3 December 2013; Revised 17 February 2014; Accepted 17 February 2014; Published 17 April 2014

Academic Editor: Robert A. Vierkant

Copyright © 2014 Wanxing Duan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Recent evidence from large cohort studies suggests that there exists a higher cancer incidence in people with type 2 diabetes (DM2). However, to date, the potential reasons for this association remain unclear. Hyperglycemia, the most important feature of diabetes, may be responsible for the excess glucose supply for these glucose-hungry cells, and it contributes to apoptosis resistance, oncogenesis, and tumor cell resistance to chemotherapy. Considering associations between diabetes and malignancies, the effect of hyperglycemia on cancer progression in cancer patients with abnormal blood glucose should not be neglected. In this paper, we describe the role that hyperglycemia plays in cancer progression and treatment and illustrate that hyperglycemia may contribute to a more malignant phenotype of cancer cells and lead to drug resistance. Therefore, controlling hyperglycemia may have important therapeutic implications in cancer patients.